


## SHIELDS NETWORK OUTCOMES\*

## Transplant

A transplant is a surgical procedure that transfers an organ, tissue, or cells from a donor to a recipient to replace damaged or failing body parts and restore health. Shields primarily follows patients with kidney, liver, heart, lung, pancreas, stem cell, and bone marrow transplants.

## What We Measure



## Why It Matters

Transplant patients frequently require hospitalization or ER are due to comorbidities, rejection, infections from post-transplant immunosuppressant medications, and inadequate coordination between transplant centers and emergency providers. Regular follow-up, monitoring by clinicians, and adherence to anti-rejection medications can prevent some transplant-related hospitalizations and ER utilization. Monitoring hospital utilization provides insight into potential unmet healthcare needs and approaches to lower the total cost of medical care.<sup>10,11</sup> Comprehensive care requires a thorough understanding of disease management. Absenteeism and adherence measurements are vital in providing insights into disease burden and quality of life effects, leading to enhanced care, improved quality of life, and reduced costs.

Shields Health Solutions Network includes data from a collective of member health systems that partner with Shields to elevate an integrated specialty oharmacy model.

dherence is measured by the proportion of days covered (PDC)

Nelson J, Alvey N, Bowman L, et al. Consensus recommendations for use of maintenance mmunosuppression in solid organ transplantation: Endorsed by the American College of Clini thotopic heart transplant patients. J Am Coll Emerg Physicia id:0.1002/emp2.12718. ihold JD, Elfadawy N, Buccini LD, et al. Emergency departme ic Nephrol. 2016;11(4):674-683. doi:10.2215/CJN.07950715.

partment use and hospital admissions among adult erg Physicians Open. 2022;3(3):e12718. sy department visits after kidney transplantation. Clin J Am 7950,715

7950715. 10. ive analysis of 1251 solid organ transplant visits to the IO(1):48-54. dication therapy management and adherence among US 11.

American Society of Rephrology. 2017;28(3):229 Safia Boghani, Kirkham H, Witt EA, et al. Medical Journal of Drug Assessment. 2019;8(sup1):77. do PQA measure overview Pharmacy Quality Allian

H, Witt EA, et al. Medication adherence and graft survival among heart transplan nent. 2019;8(sup1):7-7. doi:https://doi.org/10.1080/21556660.2019.1658329 Pharmacy Quality Alliance. rog/assate/Measures/PDA. Measures. Overview.ndf. Published 2024. Accessed (